BioWorld

Oct. 17, 2016

View Archived Issues

BioWorld stock report for public biotechnology companies

The week's biggest gainers and losers

Money raised by biotech: Jan. 1 - Oct. 14, 2016

Money raised by biotech in 2016 vs. 2015

Regulatory submissions, approvals & other actions: September 2016

Phase III clinical trials update: September 2016

Phase II clinical trials update: September 2016

Phase I clinical trials update: September 2016

Cannabinoids medicalized for multiple indications

Marijuana has been used as a medical treatment for centuries. But there’s only one cannabinoid-based drug on the market, Marinol (dronabinol, Abbvie Inc.), which was approved back in 1985. Read More

Week in review

Week in Washington

Word on the street

FDA approvals in September

Today's news in brief

BioWorld

BioWorld briefs for June 12, 2026.

Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis

BioWorld

Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...

Ethyreal launches to treat the underlying cause of Graves’, TED

BioWorld

Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...

Sanofi phase III CIDP quit dents Dianthus; C1 mismatch?

BioWorld

Investors in Dianthus Therapeutics Inc. apparently chose to ignore subtleties in the difference between efforts with that firm’s claseprubart vs. those by...

Microbiota modulates the antidepressant effects of GLP-1 analogues

BioWorld Science

Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...